Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation

• Status: Completed
• Trial end date: 2009-03-01

Summary

The aim of the study is to evaluate the efficacy of new immunosuppressive protocol based on two applications of anti-CD52 MabCampath (Alemtuzumab) a single dose of anti-TNF-α Remicade (infliximab) monoclonal antibodies in the early posttransplant period followed by either monotherapy based on tacrolimus or sirolimus.

• Phase: N/A

Details

• Lead Sponsor: Institute for Clinical and Experimental Medicine
• Collaborators: Charite University, Berlin, Germany; Miltenyi Biomedicine GmbH; Miltenyi Biotec GmbH
• Treatments: Alemtuzumab; Antibodies; Antibodies, Monoclonal; Calcineurin Inhibitors; Everolimus; Infliximab; Sirolimus; Tacrolimus